We are pleased to invite you to Clinical Insights in Cancer Genome Interpretation, a European symposium exploring one of the most critical challenges in precision oncology: translating cancer genome data into meaningful clinical decisions.
Bringing together clinicians, molecular biologists, bioinformaticians, researchers and healthcare leaders, the symposium will examine how advances in genomic interpretation, molecular tumour boards and biomarker-driven clinical trials are shaping the future of personalised cancer care.
For more information click here
Register here before 20 October
Presentation
Key focus & objectives of the symposium:
Genomic interpretation in Precision Oncology: Evaluate cutting-edge mutation interpretation pipelines, clinical decision support tools, and automated trial-matching platforms.
Multidisciplinary Taskforce: Highlight best practices for Molecular Tumor Boards to streamline collaborative clinical decision-making.
Translational Impact: Tackle the core challenges and opportunities in variant interpretation to empower healthcare professionals and directly improve patient outcomes.
By addressing the critical step of genomic interpretation from diverse clinical perspectives, this symposium equips the healthcare workforce to fully realize the promise of personalized cancer care.
Who should attend?
The symposium will be of interest to oncologists, pathologists, molecular biologists, bioinformaticians, translational researchers, clinical trial specialists, hospital leaders, patient representatives, policymakers, regulators, payers, and relevant industry stakeholders.
Topics to be covered
- Molecular profiling interpretation across the EU
- How can molecular biologists teams overcome the primary bottlenecks related to cancer genome interpretation in the clinics?
- How can molecular profiling interpretation be harmonized and standardized across diverse EU healthcare systems? Experiences with CGI-Clinics and diverse hospitals in Europe.
- Experiences from WGS/WES from CGI500genomes
- What real-world clinical insights and lessons have emerged from the WGS/WES initiative CGI500genomes?
- AI in interpretation of genome variants in oncology
- How can artificial intelligence enhance oncological variant classification while maintaining accuracy and explainability?
- Round table: expected outcomes and challenges in MTBs
- What key challenges do Molecular Tumor Boards face, and how can we optimize their operational impact on patient care?
- Clinical trials accessibility in Europe
- How can we dismantle barriers to improve patient access to biomarker-driven clinical trials across Europe?
Programme
Time (CET) Session
8:30-9:00 Registration
9:00-9:15 Welcome – Núria López-Bigas (IRB)
9:15-10:30 Challenges and solutions of genome interpretation in clinics (20 + 5 min) chaired by Étienne Rouleau & Stamatia Laidou
● Cancer Genome Interpreter: Data-Driven Variant Interpretation in Precision Oncology – Santi Demajo (Institute for Research in Biomedicine Barcelona)
● WGS-based learning care system in clinical cancer genomics – Edwin Cuppen (Hartwig Medical Foundation)
● Peter Horak (National Center for Tumor Diseases Heidelberg)
10:30-11:15 Coffee break + group picture
11:15-12:00 Molecular profiling interpretation across the EU (10 min + 5 min questions) chaired by Enrique de Álava
● Laura Mezquita – Hospital Clínic de Barcelona
● André Oswald – Medical University of Vienna
● Colin Lindsay – University of Manchester
12:00-12:45 Experiences from WGS/WES from CGI500genomes (10 min + 5 min questions) chaired by Loic Verlingue & Nadina Ortiz
● Aroa Soriano – Vall d’Hebron Institute of Research (VHIR)
● Luigi Lorini – IRCCS Humanitas Research Hospital
● Alberto Hernando – Vall d’Hebron Institute of Oncology (VHIO)
● Eduard Porta – Institut de Recerca Josep Carreras
● Antonia Kouroutzidou – Centre for Research and Technology Hellas (CERTH)
12:45-14:00 Finger lunch & networking
14:00-14:45 AI in interpretation of genome variants in oncology
● Núria López-Bigas (IRB) – AI in CGI and future of interpretation
14:45-16:00 Round table: expected outcomes and challenges in MTBs (5 min + round table) chaired by Ana Vivancos
● Alberto Hernando
● Étienne Rouleau
● Loic Verlingue
● Beatriz Bellosillo
● Adrià Lopez
16:00-16:30 Coffee break
16:30-17:15 Clinical trials accessibility in Europe (10 min + 5 min questions) chaired by Joaquim Bosch & Olbia Serra
● Núria Kotecki
● Arnaud Bayle – Klineo
● Kristoffer Staal
17:15-17:30 Closing remarks
Dinner CGI-Clinics Consortium & Speakers (partners and speakers – upon invitation only)
Poster
